Therefore, AIS appeared to provide not only prognostic value for HER2-positive breast cancer patients receiving trastuzumab-based therapy, but also provided predictive value for dual anti-HER2 therapy with a small-molecule inhibitor like lapatinib. This evidence concerns the gene ERBB2 and breast cancer.